Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
449
datasets available to search
ShareScore release 0.9.0
Dataset results
449 results for “PROLIFIC”
PROLIFIC_790157_IRIS_WP2_MAE_protein
<p>Technical data regarding the extraction of protein assisted by microwave.</p>
Dianthus prolifer Forssk. (BR0000027571392V)
Belgium Herbarium image of <a href="https://www.plantentuinmeise.be">Meise Botanic Garden</a>.
Dianthus prolifer Forssk. (BR0000010010020)
Belgium Herbarium image of <a href="https://www.plantentuinmeise.be">Meise Botanic Garden</a>.
Therapeutic activation of endothelial sphingosine 1-phosphate receptor-1 by chaperone-bound S1P suppresses proliferative retinal neovascularization
<p>Sphingosine-1-phosphate (S1P), the circulating HDL-bound lipid mediator that acts via S1P receptors (S1PR), is required for normal vascular development. The role of this signaling axis in vascular retinopathies is unclear. Here we show in a mouse model of oxygen-induced retinopathy (OIR) that endothelial overexpression of <em>S1pr1</em> suppresses while endothelial knockout of <em>S1pr1</em> worsens neovascular tuft formation. Furthermore, neovascular tufts are increased in <em>Apom<sup>-/-</sup> </em>mice which lack HDL-bound S1P while they are suppressed in <em>Apom<sup>TG</sup> </em>mice which has more circulating HDL-S1P. These results suggest that circulating HDL-S1P activation of endothelial S1PR1 suppresses neovascular pathology in OIR. Additionally, systemic administration of ApoM-Fc-bound S1P or a small molecule Gi-biased S1PR1 agonist suppressed neovascular tuft formation. Circulating HDL-S1P activation of endothelial S1PR1 may be a key protective mechanism to guard against neovascular retinopathies that occur not only in premature infants but also in diabetes and aging.</p>
Study of Efficacy and Safety of Brolucizumab Versus Panretinal Photocoagulation Laser in Patients With Proliferative Diabetic Retinopathy
ClinicalTrials.gov study NCT04278417. IPD Sharing: YES. Countries: 16. Publications: 0.
Lowering Events in Non-proliferative Retinopathy in Scotland
ClinicalTrials.gov study NCT03439345. IPD Sharing: YES. Countries: 1. Publications: 2.
Dataset - Analyzing the influence of prolific collaborations on authors productivity and visibility
<p>Dataset used in "Analyzing the influence of prolific collaborations on authors productivity and visibility" (more info in https://github.com/carolmb/influence-of-prolific-collaborations-on-authors-productivity-and-visibility).</p> <p>Based on Microsoft Academic Graph.</p> <p>Arnab Sinha, Zhihong Shen, Yang Song, Hao Ma, Darrin Eide, Bo-June (Paul) Hsu, and Kuansan Wang. 2015. An Overview of Microsoft Academic Service (MA) and Applications. In Proceedings of the 24th International Conference on World Wide Web (WWW '15 Companion). ACM, New York, NY, USA, 243-246, doi: 10.1145/2740908.2742839</p>
Human activities favour prolific life histories in both traded and introduced vertebrates
<p>Species' life histories determine population demographics and thus the probability that introduced populations establish and spread. Life histories also influence which species are most likely to be introduced, but how such 'introduction biases' arise remains unclear. Here, we investigate how life histories affect the probability of trade and introduction in phylogenetic comparative analyses across three vertebrate classes: mammals, reptiles and amphibians. We find that traded species have relatively high reproductive rates and long reproductive lifespans. Within traded species, introduced species have a more extreme version of this same life history profile. Species in the pet trade also have long reproductive lifespans but lack 'fast' traits, likely reflecting demand for rare species which tend to have slow life histories. We identify multiple species not yet traded or introduced but with life histories indicative of high risk of future trade, introduction and potentially invasion. Our findings suggest that species with high invasion potential are favoured in the wildlife trade and therefore that trade regulation is crucial for preventing future invasions.</p>
Aflibercept Injection for Proliferative Diabetic Retinopathy
ClinicalTrials.gov study NCT01805297. IPD Sharing: NO. Countries: 1. Publications: 1.
Laser-Ranibizumab-Triamcinolone for Proliferative Diabetic Retinopathy
ClinicalTrials.gov study NCT00445003. IPD Sharing: Not stated. Countries: 1. Publications: 14.
Study of Sotatercept for the Treatment of Anemia in low-or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) or Non-proliferative Chronic Myelomonocytic Leukemia (CMML)
ClinicalTrials.gov study NCT01736683. IPD Sharing: YES. Countries: 2. Publications: 1.
Prompt Panretinal Photocoagulation Versus Ranibizumab+Deferred Panretinal Photocoagulation for Proliferative Diabetic Retinopathy
ClinicalTrials.gov study NCT01489189. IPD Sharing: Not stated. Countries: 1. Publications: 17.
Evaluation of Doxycycline Verses Placebo for the Treatment of Severe Nonproliferative or Mild or Moderate Proliferative Diabetic Retinopathy
ClinicalTrials.gov study NCT00511875. IPD Sharing: Not stated. Countries: 1. Publications: 1.
"Comparing Methotrexate Usage Techniques to Prevent Proliferative Vitreoretinopaty After Retinal Detachment Vitrectomy"
ClinicalTrials.gov study NCT06289205. IPD Sharing: YES. Countries: 1. Publications: 3.
Safety and Efficacy of Nivolumab in Treating Oral Proliferative Verrucous Leukoplakia
ClinicalTrials.gov study NCT03692325. IPD Sharing: NO. Countries: 1. Publications: 1.
Study of Ravulizumab in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)
ClinicalTrials.gov study NCT04564339. IPD Sharing: NO. Countries: 12. Publications: 2.
Intravitreal Aflibercept for Retinal Non-Perfusion in Proliferative Diabetic Retinopathy
ClinicalTrials.gov study NCT02863354. IPD Sharing: NO. Countries: 1. Publications: 15.
Study of ALXN2050 in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)
ClinicalTrials.gov study NCT05097989. IPD Sharing: UNDECIDED. Countries: 16. Publications: 2.
Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy (N)
ClinicalTrials.gov study NCT00996437. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Avastin for PDR (Proliferative Diabetic Retinopathy)
ClinicalTrials.gov study NCT01270542. IPD Sharing: Not stated. Countries: 1. Publications: 2.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.